Abstract
Duchenne muscular dystrophy (DMD) is characterized by the loss of a functional dystrophin protein; the muscles of DMD patients progressively degenerate as a result of mechanical stress during contractions, and the condition eventually leads to premature death. By means antisense oligonucleotides (AONs), it is possible to modulate pre-mRNA splicing eliminating mutated exons and restoring dystrophin open reading frame. To overcome the hurdles in using AONs for therapeutic interventions, we exerted engineered human DMD stem cells with a lentivirus, which permanently and efficiently delivered the cloned AONs. Here we describe for the first time the exosome-mediated release of AONs from engineered human DMD CD133+ stem cells allowing the rescue of murine dystrophin expression. Finally, upon release, AONs could be internalized by host cells suggesting a potential role of exosomes acting as vesicular carriers for DMD gene therapy.
Keywords: Bystander effect, Myogenic stem cells, Delivery of exon skipping machinery.
Current Gene Therapy
Title:Stem Cell-Mediated Exon Skipping of the Dystrophin Gene by the Bystander Effect
Volume: 15 Issue: 6
Author(s): Mirella Meregalli, Andrea Farini, Clementina Sitzia, Cyriaque Beley, Paola Razini, Letizia Cassinelli, Federica Colleoni, Paola Frattini, Nadia Santo, Elisabetta Galbiati, Davide Prosperi, Alessandro Tavelli, Marzia Belicchi, Luis Garcia and Yvan Torrente
Affiliation:
Keywords: Bystander effect, Myogenic stem cells, Delivery of exon skipping machinery.
Abstract: Duchenne muscular dystrophy (DMD) is characterized by the loss of a functional dystrophin protein; the muscles of DMD patients progressively degenerate as a result of mechanical stress during contractions, and the condition eventually leads to premature death. By means antisense oligonucleotides (AONs), it is possible to modulate pre-mRNA splicing eliminating mutated exons and restoring dystrophin open reading frame. To overcome the hurdles in using AONs for therapeutic interventions, we exerted engineered human DMD stem cells with a lentivirus, which permanently and efficiently delivered the cloned AONs. Here we describe for the first time the exosome-mediated release of AONs from engineered human DMD CD133+ stem cells allowing the rescue of murine dystrophin expression. Finally, upon release, AONs could be internalized by host cells suggesting a potential role of exosomes acting as vesicular carriers for DMD gene therapy.
Export Options
About this article
Cite this article as:
Meregalli Mirella, Farini Andrea, Sitzia Clementina, Beley Cyriaque, Razini Paola, Cassinelli Letizia, Colleoni Federica, Frattini Paola, Santo Nadia, Galbiati Elisabetta, Prosperi Davide, Tavelli Alessandro, Belicchi Marzia, Garcia Luis and Torrente Yvan, Stem Cell-Mediated Exon Skipping of the Dystrophin Gene by the Bystander Effect, Current Gene Therapy 2015; 15 (6) . https://dx.doi.org/10.2174/1566523215666150929111400
DOI https://dx.doi.org/10.2174/1566523215666150929111400 |
Print ISSN 1566-5232 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-5631 |
Call for Papers in Thematic Issues
Programmed Cell Death Genes in Oncology: Pioneering Therapeutic and Diagnostic Frontiers (BMS-CGT-2024-HT-45)
Programmed Cell Death (PCD) is recognized as a pivotal biological mechanism with far-reaching effects in the realm of cancer therapy. This complex process encompasses a variety of cell death modalities, including apoptosis, autophagic cell death, pyroptosis, and ferroptosis, each of which contributes to the intricate landscape of cancer development and ...read more
Related Journals
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Inhibitors of HDACs - Effective Drugs Against Cancer?
Current Cancer Drug Targets Telomere Maintenance as Therapeutic Target in Embryonal Tumours
Anti-Cancer Agents in Medicinal Chemistry A Review on Mechanisms of Anti Tumor Activity of Chalcones
Anti-Cancer Agents in Medicinal Chemistry Crosstalk of Long Non-coding RNAs and EMT: Searching the Missing Pieces of an Incomplete Puzzle for Lung Cancer Therapy
Current Cancer Drug Targets CCR5 as a Potential Target in Cancer Therapy: Inhibition or Stimulation?
Anti-Cancer Agents in Medicinal Chemistry SCYL1-BP1 Affects Cell Cycle Arrest in Human Hepatocellular Carcinoma Cells via Cyclin F and RRM2
Anti-Cancer Agents in Medicinal Chemistry Compartmentalized Platforms for Neuro-Pharmacological Research
Current Neuropharmacology Searching for Novel Cancer Chemopreventive Plants and their Products:The Genus Zanthoxylum
Current Drug Targets Meet Our Editorial Board Member:
Recent Patents on Anti-Infective Drug Discovery Recent Patents Therapeutic Agents for Cancer
Recent Patents on Anti-Cancer Drug Discovery Recent Developments Towards the Synthesis of Varitriol: An Antitumour Agent from Marine Derived Fungus Emericella Variecolor
Current Organic Synthesis Betulinic Acid and Brosimine B Hybrid Derivatives as Potential Agents against Female Cancers
Anti-Cancer Agents in Medicinal Chemistry Is the Cytoskeleton an Intracellular Receptor for Adrenomedullin and PAMP?
Current Protein & Peptide Science The Role of miR-129-5p in Cancer: A Novel Therapeutic Target
Current Molecular Pharmacology Perspectives On Membrane-associated Progesterone Receptors As Prospective Therapeutic Targets
Current Drug Targets HIV Vaccine Efficacy and Immune Correlates of Risk
Current HIV Research Interleukin-15 in Gene Therapy of Cancer
Current Gene Therapy Critical microRNAs in Lung Cancer: Recent Advances and Potential Applications
Anti-Cancer Agents in Medicinal Chemistry Matrix Metalloproteinase Inhibitors: New Challenges in the Era of Post Broad-Spectrum Inhibitors
Current Pharmaceutical Design Research Advances in the Treatment of Melanoma by Treat Melanoma
Current Topics in Medicinal Chemistry